Evidence map›Paper›PMID 19936230›Full record

ArticlePloS one2009

Pseudomonas aeruginosa population structure revisited.

Jean-Paul Pirnay, Florence Bilocq, Bruno Pot, Pierre Cornelis, Martin Zizi, Johan Van Eldere, Pieter Deschaght, Mario Vaneechoutte, Serge Jennes, Tyrone Pitt and 1 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 144 papers.

0numbers the graph read from it
0cells of the map it votes in
144citing papers in PubMed
5.7field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

144 citing papers in PubMed, 294 citations in OpenAlex.

  1. Intrapulmonary percussive ventilation improves lung function in cystic fibrosis patients chronically colonized with Pseudomonas aeruginosa: a pilot cross-over study.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2018
    Trial
  2. Trial
  3. L2 β-lactamase contributes to ceftolozane-tazobactam resistance inAntimicrobial agents and chemotherapy · 2026
    Article
  4. Article
  5. Global epidemiology of carbapenem-resistantJAC-antimicrobial resistance · 2026
    Review
  6. Article
  7. Beyond Resistance Genes:Life (Basel, Switzerland) · 2026
    Review
  8. Article
  9. Article
  10. A novel mechanism of ceftolozane-tazobactam resistance inbioRxiv : the preprint server for biology · 2026
    Article
  11. Article
  12. Article
  13. Article
  14. Interference ofPharmaceuticals (Basel, Switzerland) · 2025
    Article
  15. Article
  16. Review
  17. Article
  18. New Insights inAntibiotics (Basel, Switzerland) · 2025
    Article
  19. Article
  20. International journal of molecular sciences · 2025
    Review

84 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 1 country.

Jean-Paul PirnayLaboratory for Molecular and Cellular Technology, Burn Centre, Queen Astrid Military Hospital, Brussel, Belgium. jean-paul.pirnay@mil.be
Florence Bilocq
Bruno Pot
Pierre Cornelis
Martin Zizi
Johan Van Eldere
Pieter Deschaght
Mario Vaneechoutte
Serge Jennes
Tyrone Pitt
Daniel De Vos
Queen Astrid Military Hospital · BEVrije Universiteit Brussel · BEGhent University Hospital · BEKU Leuven · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

At present there are strong indications that Pseudomonas aeruginosa exhibits an epidemic population structure; clinical isolates are indistinguishable from environmental isolates, and they do not exhibit a specific (disease) habitat selection. However, some important issues, such as the worldwide emergence of highly transmissible P. aeruginosa clones among cystic fibrosis (CF) patients and the spread and persistence of multidrug resistant (MDR) strains in hospital wards with high antibiotic pressure, remain contentious. To further investigate the population structure of P. aeruginosa, eight parameters were analyzed and combined for 328 unrelated isolates, collected over the last 125 years from 69 localities in 30 countries on five continents, from diverse clinical (human and animal) and environmental habitats. The analysed parameters were: i) O serotype, ii) Fluorescent Amplified-Fragment Length Polymorphism (FALFP) pattern, nucleotide sequences of outer membrane protein genes, iii) oprI, iv) oprL, v) oprD, vi) pyoverdine receptor gene profile (fpvA type and fpvB prevalence), and prevalence of vii) exoenzyme genes exoS and exoU and viii) group I pilin glycosyltransferase gene tfpO. These traits were combined and analysed using biological data analysis software and visualized in the form of a minimum spanning tree (MST). We revealed a network of relationships between all analyzed parameters and non-congruence between experiments. At the same time we observed several conserved clones, characterized by an almost identical data set. These observations confirm the nonclonal epidemic population structure of P. aeruginosa, a superficially clonal structure with frequent recombinations, in which occasionally highly successful epidemic clones arise. One of these clones is the renown and widespread MDR serotype O12 clone. On the other hand, we found no evidence for a widespread CF transmissible clone. All but one of the 43 analysed CF strains belonged to a ubiquitous P. aeruginosa "core lineage" and typically exhibited the exoS(+)/exoU(-) genotype and group B oprL and oprD alleles. This is to our knowledge the first report of an MST analysis conducted on a polyphasic data set.

Indexed as

AnimalsBacterial Typing TechniquesCystic FibrosisDrug Resistance, MultipleGene Expression ProfilingGene Expression Regulation, BacterialGenes, BacterialGenetic VariationGenome, BacterialHumansPolymerase Chain ReactionPolymorphism, Restriction Fragment LengthPseudomonas aeruginosaPseudomonas InfectionsRecombination, Genetic

Identifiers

PMID19936230
PMCPMC2777410
OpenAlexW1982118335

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.